Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cooling caps may keep hair on during pancreatic cancer chemo

NCT ID NCT04492800

Symptom relief Sponsor: HonorHealth Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a scalp cooling device (Paxman) to prevent hair loss in 9 people with advanced pancreatic cancer receiving chemotherapy. The goal was to see if the cap could keep hair loss mild (less than 50% hair loss) and improve comfort. Results focused on hair preservation and patient distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Dec 2019

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent/assent for the trial * \>18 years of age on day of signing informed consent * Diagnosis of pancreatic cancer and scheduled to receive treatment with a regimen containing nab-paclitaxel, gemcitabine and cisplatin Exclusion Criteria: * Grade 1 alopecia * Existing history of scalp metastases or the presence of scalp metastases is suspected * No history of previous cancers within the past 5 years * Central Nervous System (CNS) malignancies (either primary or metastatic) * Cold sensitivity, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, cold migraine, cold urticaria, post-traumatic cold dystrophy * Imminent bone marrow ablation chemotherapy * Imminent skull radiation * Previously received or scheduled to undergo skull irradiation * Severe liver or renal disease from any etiology as patient may not be able to metabolize or clear the metabolites of the chemotherapeutic agent * Skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma * Small cell carcinoma of the lung * Solid tumors that have a high likelihood for metastasis in transit * Squamous cell carcinoma of the lung

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm alopecia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia

Contacts and locations

Locations

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.